ClinicalTrials.gg
RecruitingNCT07417189Updated Mar 11, 2026

A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )

A Phase 1/2 interventional study of ABSK141-400mg and ABSK141-Recommended Dose for Expansion (RDE) in Solid Tumors, Adult, sponsored by Abbisko Therapeutics Co, Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
401
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human (FIH), exploratory, multicenter, open-label, phase I/II study of ABSK141 in patients with advanced solid tumors to to evaluate safety, tolerability, PK and optimize the dosage.

Read the detailed description

The study will start with a dose escalation of oral ABSK141 in patients with advanced solid tumors harboring KRAS G12D mutation to evaluate safety, tolerability, and PK. The expansion part will investigate oral ABSK141 at the recommended doses for expansion (RDEs) to evaluate safety and efficacy among selected tumor types harboring KRAS G12D mutation and optimize the dosage.

The phase II study will further investigate oral ABSK141 at the recommended phase 2 doses (RP2Ds) to evaluate safety and efficacy among selected tumor types harboring KRAS G12D mutation.

02

Conditions studied

  • Solid Tumors, Adult

Keywords

  • ABSK141
  • KRAS G12D
03

In context

Lead sponsor

Abbisko Therapeutics Co, Ltd is the lead sponsor of 38 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Patients should understand, sign, and date the written form prior to screening
  2. Male or female age 18 years or older
  3. Patients with confirmed locally-advanced or solid tumors .

For backfill cohorts in the escalation part:

  1. Patients must have the following solid tumor harboring KRAS G12D mutation:

    1. Colorectal cancer (CRC);
    2. Non-small cell lung cancer (NSCLC);
    3. Pancreatic ductal adenocarcinoma (PDAC);
  2. Patients must have at least one measurable target lesion according to 1.1

For expansion Part:

  1. Patients must have the following solid tumor harboring KRAS G12D mutation:

    1. Colorectal cancer (CRC);
    2. Non-small cell lung cancer (NSCLC);
    3. Pancreatic ductal adenocarcinoma (PDAC);
    4. Other solid tumors;
  2. Patients must have at least one measurable target lesion according to RECIST 1.1

For phase II:

  1. Patients with locally advanced or metastatic solid tumors confirmed by histological examination, whose disease has progressed after standard treatment or who are intolerant to standard treatment, or for whom there is currently no standard treatment.
  2. Patients must have the following solid tumor harboring KRAS G12D mutation:

    1. Colorectal cancer (CRC);
    2. Non-small cell lung cancer (NSCLC);
    3. Pancreatic ductal adenocarcinoma (PDAC);
    4. Other solid tumors;
  3. Patients must have at least one measurable target lesion according to RECIST 1.1 4. performance status 0 or 1 5. Adequate organ function and bone marrow function as indicated by the following screening assessments performed within 14 days prior to the first dose of study drug 6. For patients participating exploration of food effect:

(1) be able to eat a standardized high-fat, high caloric meal within 30 minutes (2) be able to fast for 10 hours

Exclusion Criteria:

  1. Known allergy or to any component of the product
  2. (For backfill cohorts and expansion part) Patients who were previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy
  3. Has a known additional that is progressing or has required active treatment
  4. Unable to swallow capsules or tablets or malabsorption syndrome, disease significantly affecting GI function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction. If any of these conditions exist, the site should discuss with the sponsor to determine patient eligibility
  5. Previous anti-tumor therapy, including chemotherapy, endocrine therapy, molecular targeted therapy or other investigational drugs received ≤2 weeks or ≤5-half life (whichever is shorter), radiotherapy and antibody therapy received ≤4 weeks prior to initiation of study treatment
  6. Major surgery within 4 weeks of the first dose of study drug. Note that all surgical wounds must be healed and free of infection or dehiscence
  7. Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy, that have not regressed to Grade ≤1 severity ( v5.0)
  8. Patients should not use proton pump inhibitors for at least 7 days prior to the first dose of ABSK141 and during treatment with ABSK141.
  9. P-gp inhibitor and strong inhibitors to 7 days or 5 half-lives whichever is longer and for CYP3A inducers to 2 weeks or 5 half-lives
  10. Active central nervous system (CNS) metastases
  11. History of interstitial lung disease requiring systemic treatment.
  12. Impaired cardiac function or cardiac disease
  13. NSCLC cohorts: Patient previously identified as having a driver mutation (according to local standard of care or guidelines) and have not received any targeted therapy, for example: EGFR mutation, ALK rearrangement, KRAS G12C mutation, NTRK1/2/3 gene fusion, RET fusion, MET exon14 skipping mutation, BRAF V600E mutation, ROS1 rearrangement, etc
  14. Known acquired immunodeficiency syndrome (AIDS)-related illness, or positive test for 1/2 antibody
  15. Exclusion of hepatitis infection
  16. Patients with /uncontrolled ascites or pleural effusion
  17. Pregnant or nursing (lactating) women
  18. refuse to use highly effective methods of during the study and for up to 6 months after the last dose of study drug.
  19. Sexually active males who refuse to use a condom during intercourse while taking drug and for 5 consecutive compound half-lives plus 60 days after stopping study drug.
  20. Vaccination with a live, attenuated vaccine within 4 weeks prior to the first dose of study treatment except for administration of inactivate vaccines
  21. Planned major surgery during study treatment
  22. Any other clinically significant comorbidities
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
401 participants (estimated)

Study arms

  • Experimental
    Escalation part-400mg

    ABSK141 (investigational drug) tablet, 400 mg administered orally once daily (QD), continuously until disease progression.

    Drug: ABSK141-400mg

  • Experimental
    expansion part

    ABSK141 (investigational drug) tablet,Recommended Dose for Expansion (RDE) administered orally once daily (QD), continuously until disease progression.

    Drug: ABSK141-Recommended Dose for Expansion (RDE)

  • Experimental
    Escalation part-800mg

    ABSK141 (investigational drug) tablet, 800 mg administered orally once daily (QD), continuously until disease progression.

    Drug: ABSK141-800mg

  • Experimental
    Escalation part-1200mg

    ABSK141 (investigational drug) tablet, 1200 mg administered orally once daily (QD), continuously until disease progression.

    Drug: ABSK141-1200mg

  • Experimental
    Backfill cohorts

    ABSK141 (investigational drug) tablet, The decision-making on doses for backfill cohorts will be based on the discussion and alignment between the Sponsor and Investigator.

    Drug: ABSK141-Recommended Dose for Expansion (RDE)

  • Experimental
    Phase II

    ABSK141 (investigational drug) tablet, administered at the Recommended Phase 2 Dose (RP2D) continuously until disease progression.

    Drug: ABSK141-Recommended Phase 2 dose (RP2D)

Interventions

  • DrugABSK141-400mg

    In the escalation part#patients will first orally receive a single dose of ABSK141 on D-3, followed by a three-day run-in period to assess the PK profile of singledose ABSK141 400mg administration. Thereafter, patients will continuously receive ABSK141 400mg once daily (QD).

    Also known as: ABSK141, investigational drug

  • DrugABSK141-Recommended Dose for Expansion (RDE)

    In the expansion part# patients will orally receive ABSK141 at the recommended dose for expansion (RDE).patients will continuously receive ABSK141 Recommended Dose for Expansion (RDE) once daily (QD).

    Also known as: ABSK141, investigational drug

  • DrugABSK141-800mg

    In the escalation part#patients will first orally receive a single dose of ABSK141 on D-3, followed by a three-day run-in period to assess the PK profile of singledose ABSK141 800mg administration. Thereafter, patients will continuously receive ABSK141 800mg once daily (QD).

    Also known as: ABSK141, investigational drug

  • DrugABSK141-1200mg

    In the escalation part#patients will first orally receive a single dose of ABSK141 on D-3, followed by a three-day run-in period to assess the PK profile of singledose ABSK141 1200mg administration. Thereafter, patients will continuously receive ABSK141 1200mg once daily (QD).

    Also known as: ABSK141, investigational drug

  • DrugABSK141-Recommended Phase 2 dose (RP2D)

    Phase II #patients will orally receive ABSK141 at the Recommended Phase 2 Dose (RP2D).

    Also known as: ABSK141, investigational drug

06

What researchers measure

Primary outcomes

  1. Incidence of DLTs

    dose-limiting toxicities

    Time frame: from Run-in to Day28

  2. Incidence and severity of AEs

    Adverse events

    Time frame: from the time that the patient provides informed consent through and including 30 days after the last administration of ABSK141.

  3. Incidence and severity of SAEs

    serious adverse events

    Time frame: from the time that the patient provides informed consent through and including 30 days after the last administration of ABSK141.

Secondary outcomes

  1. Cmax

    maximum observed concentration

    Time frame: From pre-dose to up to 72 hours post-dose

  2. AUC

    area under the concentration-time curve

    Time frame: From pre-dose to up to 72 hours post-dose

  3. t1/2

    elimination half-life

    Time frame: From pre-dose to up to 72 hours post-dose

  4. CL/F

    apparent oral clearance

    Time frame: From pre-dose to up to 72 hours post-dose

  5. tmax

    time to maximum observed concentration

    Time frame: From pre-dose to up to 72 hours post-dose

  6. ORR

    Objective response rate

    Time frame: From the first dose date to the date of first confirmed response (CR/PR), assessed up to 24 months.

  7. DOR

    Duration of response

    Time frame: From date of first confirmed response (CR/PR) to date of first documented progression (PD) or death from any cause, whichever comes first, assessed up to 24 months.

  8. PFS

    Progression-free survival

    Time frame: From the first dose date to the date of first documented progressive disease (PD) or death from any cause, whichever occurs first, assessed up to 24 months.

  9. DCR

    Disease control rate

    Time frame: From the first dose date to the date of first documented disease status assessment (CR/PR/SD/PD), assessed up to 24 months.

  10. OS

    Overall survival

    Time frame: From the first dose date to the date of death from any cause, assessed up to24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 18, 2026
StartActual
Mar 2, 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Jul 30, 2029
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07417189
Responsible party
Sponsor
First posted
Feb 18, 2026
Start date
Mar 2, 2026
Primary completion
Dec 30, 2028 (estimated)
Completion
Jul 30, 2029 (estimated)
Last update
Mar 11, 2026

Study contacts

Yu Zhang, Bachelor
Contact
yuco.zhang@abbisko.com
+86-021-68912098
Xianjun Yu, Doctor
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion